AZN vs IVA

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.

Inventiva S.A. presents a classic high-risk, high-reward biotechnology profile, characterized by a stable but mediocre Piotroski F-Score of 4/9 and a complete absence of traditional value metrics. While the company suffers from extreme financial instability—evidenced by a negative Price/Book ratio of -71.74 and a staggering Price/Sales ratio of 137.80—it maintains a 'Strong Buy' consensus from 13 analysts with a target price of $15.13. The disconnect between the bearish technical trend (0/100) and the bullish analyst outlook suggests the valuation is driven by pipeline expectations rather than current fundamentals. Consequently, the stock is a speculative play on clinical success rather than a data-driven financial investment.